DORIS TAYLOR
Doris Taylor is a pioneer and global thought leader in regenerative medicine, holding over 20 patents in the field. She is credited with the first scientific repair of injured hearts with stem cells in 1998. Her group further transformed the field of organ transplantation science in 2008 by developing a unique cell removal (decellularization) method that makes un-transplantable organs into usable scaffold frameworks for building new organs with stem cells. This was so revolutionary that it was recognized as one of the “Top 10 Research Advances” by the American Heart Association, and Taylor was nominated as one of the “100 most influential people in the world” by Time magazine. Next, she turned to disease prevention and has begun to develop “cellular signatures” of heart disease and aging that appear to differ by sex, race, and ethnicity.
Taylor is passionate about creating cures for heart disease, which kills more people worldwide than any other disease and has an estimated economic impact of 219 billion dollars annually. In 2021, Taylor cofounded a new biotech, Organamet Bio Inc., whose mission is to cure heart disease and reduce healthcare costs. Her first goal is to bioengineer personalized replacement hearts on demand. She is equally committed to making those therapies available fairly, equitably, and as soon as they are shown to be safe and effective.
She has sat on numerous think tanks and international scientific committees, including for the NIH, the FDA, the American Association of Blood Banks, and the Alliance for Regenerative Medicine. Taylor is a member of the Leadership Advisory Committee for the Advanced Regenerative Manufacturing Institute (ARMI) and sat for almost 2 decades on the international jury for the Institut de France LeFoulon-Delalande Foundation Grand Prix, which is awarded annually to individuals making worldwide contributions to cardiovascular medicine.
Her motto is, “Build the Future Today – and Do It With Heart.”
SPEAKING IN SESSION:
"Building hearts 'on demand" - Day one, 3:40PM